BioMedNewsBreaks Archive - BioMedWire (BMW)

TuesdayJan 27, 2026 10:10 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s pipeline, operations and capital allocation priorities. The letter emphasizes a disciplined, patient-first approach centered on optimizing TPI 287 as the Company’s lead asset, refining its development and regulatory pathway, prioritizing high-value indications, and aligning resources toward milestone-driven execution, while also selectively evaluating pipeline expansion opportunities to support long-term shareholder value creation. To view the full press release, visit https://ibn.fm/mEy9f About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline…

FridayJan 23, 2026 9:10 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages IBN for Corporate Communications Support

Earth Science Tech (OTC: ETST), a strategic holding company advancing a portfolio of operating businesses within regulated healthcare markets, announced that it has engaged InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, to assist with its corporate communications strategy, reflecting the company’s focus on execution, compliance and disciplined scaling across licensed pharmaceutical compounding, digital health and telemedicine platforms, specialty healthcare services and complementary assets, with hands-on operational oversight through wholly owned and majority-owned subsidiaries aimed at building sustainable revenue streams and long-term shareholder value. To view the full press release, visit https://ibn.fm/5qFTn About Earth Science Tech, Inc. Earth Science…

ThursdayJan 22, 2026 9:25 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care through actionable cardiac insights, announced the appointment of Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. In the newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia assessment, heart attack detection indication and a 12-lead ECG extended wear patch monitor, while expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption. To view the full press release, visit https://ibn.fm/9YzeT About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical…

WednesdayJan 21, 2026 1:30 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology

Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. “Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (‘SABCS’), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use,” reads a recent article. “The platform shows high-level compatibility across different therapeutic categories. All five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor(R)), and umirolimus, formed stable,…

TuesdayJan 20, 2026 12:53 pm

BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference

Lixte Biotechnology Holdings (NASDAQ: LIXT) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, in Atlantic City, N.J. The company said Chief Executive Officer Geordan Pursglove will conduct one-on-one meetings with investors during the conference as LIXTE continues advancing LB-100, its first-in-class inhibitor of protein phosphatase 2A, through clinical development. To view the full press release, visit https://ibn.fm/K3ih2 About Lixte Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly…

FridayJan 16, 2026 11:56 am

BioMedNewsBreaks — Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A) Engages IBN for Corporate Communications and Awareness

Disseminated on behalf of Diagnos Inc. and may include paid advertising. Diagnos (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A), a pioneer in early detection of critical health issues using Artificial Intelligence-based technology, announced it has engaged Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions. Under the one-year agreement effective Jan. 10, 2026, IBN will receive monthly compensation of US$6,400, payable in advance in cash from the Corporation’s funds. IBN will assist Diagnos in refining and strengthening its market awareness profile with the objective of maximizing shareholder value, is acting at arm’s length, and, together with its principals, holds no direct or indirect interest in the Corporation’s securities. The engagement remains subject to acceptance by…

WednesdayJan 14, 2026 9:40 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has licensed regulatory-grade real-world evidence drawn from more than 70,000 U.S. patients treated with intravenous ketamine or nasal S-ketamine for depression and suicidal ideation to support its application for Accelerated Approval of NRX-100, a preservative-free ketamine, under Fast Track Designation. The dataset, provided by Osmind, includes nearly one million treatment sessions and extensive longitudinal safety and effectiveness data and will be submitted to the U.S. Food and Drug Administration following a 2025 policy update allowing de-identified real-world evidence. NRx is seeking approval of NRX-100 for the treatment of suicidal ideation in depression, including bipolar…

WednesdayJan 14, 2026 9:10 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026

Oragenics (NYSE American: OGEN) announced that it will present at the upcoming Sequire Investor Summit 2026, scheduled for Jan. 20–22, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. During the conference, the Company plans to highlight its novel approach to addressing the significant unmet medical need in concussion and mild traumatic brain injury, including progress toward advancing its ONP-002 clinical program into Phase 2a studies, an area where no approved drug therapies currently exist, according to Oragenics Chief Executive Officer Janet Huffman. To view the full press release, visit https://ibn.fm/Gn84M About Oragenics, Inc. Oragenics, Inc. is a…

TuesdayJan 13, 2026 10:30 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Need for Broad-Spectrum Antivirals Amid Severe Influenza Season

NanoViricides, Inc. (NYSE American: NNVC) said the current severe influenza wave underscores the urgent need for broad-spectrum antiviral therapies capable of addressing influenza, RSV, coronaviruses and other respiratory viruses, citing limitations of seasonal vaccines and existing antivirals that face timing constraints and resistance risks. The Company highlighted its Phase II-stage drug candidate NV-387, a broad-spectrum nanoviricide designed to mimic host-cell features viruses rely on to infect cells, which management believes positions it as a potential first-line, empirical therapy for viral acute and severe acute respiratory infections, with demonstrated preclinical activity against influenza, RSV and coronaviruses and potential applicability across a…

TuesdayJan 13, 2026 9:40 am

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on advancing differentiated cancer therapies, announced that it has engaged IBN, a multifaceted financial news and publishing company, to support its corporate communications strategy. Through the engagement, IBN will leverage its investor-focused distribution platform, including more than 5,000 syndication outlets, newsletters, social media channels, blogs and wire services via InvestorWire, to increase awareness of LIXTE’s first-in-class approach to enhancing the effectiveness of existing chemotherapy and immunotherapy treatments, including its lead clinical candidate, LB-100, across cancers with significant unmet medical need. To view the full press release, visit https://ibn.fm/xtCUR About LIXTE…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages IBN for Corporate Communications Support

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer

BioMedNewsBreaks — Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology

BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference

BioMedNewsBreaks — Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A) Engages IBN for Corporate Communications and Awareness

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Need for Broad-Spectrum Antivirals Amid Severe Influenza Season

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search